Abstract
Background
Tyrosine kinase inhibitors are currently the most widely studied targeted therapies for gastric cancer. As a triple tyrosine inhibitor, nintedanib can alleviate the progression of a variety of cancers, but it is poorly studied in gastric cancer.
Aims
To investigate the effect of nintedanib on gastric cancer.
Methods
This study investigated nintedanib’s effect on gastric cancer autophagy in vivo and in vitro, and the activity and morphological changes of gastric cancer cells were detected by MTT and HE staining. Proliferation, migration, invasion, and EMT-related marker proteins of AGS and MKN-28 cells were detected. The effects of nintedanib on autophagy in gastric cancer cells were detected by acridine orange, immunofluorescence, and Western blotting assays. The regulation of nintedanib on STAT3 and Beclin1 was detected by qPCR and Western blotting assays. Subsequently, the effects of nintedanib on the tumor STAT3/Beclin1 pathway were verified by stably overexpressing STAT3 in gastric cancer cell lines and tumor-bearing experiments in nude mice.
Results
The results showed that nintedanib could inhibit gastric cancer cells’ proliferation and EMT process. Meanwhile, autophagy was induced in AGS and MKN-28 cells, and the expression of autophagy-related protein Beclin1 was upregulated, and the phosphorylation level of STAT3 was downregulated. Nintedanib inhibited STAT3 phosphorylation and upregulated Beclin1 to inhibit tumor growth in gastric cancer cell lines with stable STAT3 overexpression and tumor-bearing experiments in nude mice.
Conclusions
By inhibiting STAT3, nintedanib upregulated Beclin1 and caused autophagic death in gastric cancer cells.
Similar content being viewed by others
Data availability
The datasets used in the current study are available from the corresponding author upon reasonable request.
References
Stahl P, Seeschaaf C, Lebok P, Kutup A, Bockhorn M, Izbicki JR et al. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol 2015;15:7.
Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387–4393.
McCormack PL. Nintedanib: first global approval. Drugs 2015;75:129–139.
Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774–4782.
Won E, Basunia A, Chatila WK, Hechtman JF, Chou JF, Ku GY et al. Efficacy of combined VEGFR1-3, PDGFα/β, and FGFR1-3 blockade using nintedanib for esophagogastric cancer. Clin Cancer Res 2019;25:3811–3817.
Awasthi N, Schwarz MA, Zhang C, Schwarz RE. Augmentation of Nab-paclitaxel chemotherapy response by mechanistically diverse antiangiogenic agents in preclinical gastric cancer models. Mol Cancer Ther 2018;17:2353–2364.
Shimizu S, Yoshida T, Tsujioka M, Arakawa S. Autophagic cell death and cancer. Int J Mol Sci 2014;15:3145–3153.
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 2018;25:486–541.
You L, Wang Z, Li H, Shou J, Jing Z, Xie J et al. The role of STAT3 in autophagy. Autophagy 2015;11:729–739.
Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL et al. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death Dis 2013;4:e485.
Rangarajan S, Kurundkar A, Kurundkar D, Bernard K, Sanders YY, Ding Q et al. Novel mechanisms for the antifibrotic action of nintedanib. Am J Respir Cell Mol Biol 2016;54:51–59.
Ashrafizadeh M, Zarrabi A, Orouei S, Zarrin V, Rahmani Moghadam E, Zabolian A et al. STAT3 pathway in gastric cancer: signalling, therapeutic targeting and future prospects. Biology (Basel) 2020;9:126.
Rao X, Huang X, Zhou Z, Lin X. An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinform Biomath 2013;3:71–85.
Jensen MM, Jørgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging 2008;8:16.
Kato R, Haratani K, Hayashi H, Sakai K, Sakai H, Kawakami H et al. Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts. Br J Cancer 2021;124:914–924.
Zhang P, Zheng Z, Ling L, Yang X, Zhang N, Wang X et al. w09, a novel autophagy enhancer, induces autophagy-dependent cell apoptosis via activation of the EGFR-mediated RAS-RAF1-MAP2K-MAPK1/3 pathway. Autophagy 2017;13:1093–1112.
Wei B, Huang QY, Huang SR, Mai W, Zhong XG. MicroRNA-34a attenuates the proliferation, invasion and metastasis of gastric cancer cells via downregulation of MET. Mol Med Rep 2015;12:5255–5261.
Tanida I, Ueno T, Kominami E. LC3 and autophagy. Methods Mol Biol 2008;445:77–88.
Fu LL, Cheng Y, Liu B. Beclin-1: autophagic regulator and therapeutic target in cancer. Int J Biochem Cell Biol 2013;45:921–924.
Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol 2016;17:611–625.
Yu J, Zhang Y, Leung LH, Liu L, Yang F, Yao X. Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis. J Hematol Oncol 2016;9:111.
Lian L, Li XL, Xu MD, Li XM, Wu MY, Zhang Y et al. VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer. BMC Cancer 2019;19:183.
Grojean M, Schwarz MA, Schwarz JR, Hassan S, von Holzen U, Zhang C et al. Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models. J Cell Mol Med 2021;25:4950–4961.
Kodama M, Kitadai Y, Sumida T, Ohnishi M, Ohara E, Tanaka M et al. Expression of platelet-derived growth factor (PDGF)-B and PDGF-receptor β is associated with lymphatic metastasis in human gastric carcinoma. Cancer Sci 2010;101:1984–1989.
Higuchi A, Oshima T, Yoshihara K, Sakamaki K, Aoyama T, Suganuma N et al. Clinical significance of platelet-derived growth factor receptor-β gene expression in stage II/III gastric cancer with S-1 adjuvant chemotherapy. Oncol Lett 2017;13:905–911.
Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 2011;18:571–580.
Hatano M, Tokuda K, Kobayashi Y, Yamashiro C, Uchi SH, Kobayashi M et al. Inhibitory effect of nintedanib on VEGF secretion in retinal pigment epithelial cells induced by exposure to a necrotic cell lysate. PLoS ONE 2019;14:e0218632.
Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyàs E et al. Silibinin suppresses tumor cell-intrinsic resistance to nintedanib and enhances its clinical activity in lung cancer. Cancers (Basel) 2021;13:4168.
Liu Y, Shoji-Kawata S, Sumpter RM Jr, Wei Y, Ginet V, Zhang L et al. Autosis is a Na+, K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. Proc Natl Acad Sci USA 2013;110:20364–20371.
Acknowledgments
Not applicable.
Funding
No funding.
Author information
Authors and Affiliations
Contributions
HZ and MMX designed the study and developed the methodology. HZ, MMX, and KHT performed the experiments and collected the data, analyzed and interpreted the data, and wrote the original draft. WBL interpreted the data and critically reviewed the manuscript. All authors have read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
There is no conflict of interest for any of the authors.
Ethical approval
Ethic Approval is approved by Ningbo University Animal Testing Center (Grant Number NBU20220118).
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Zhu, H., Xia, MM., Tong, KH. et al. Nintedanib Induces the Autophagy-Dependent Death of Gastric Cancer Cells by Inhibiting the STAT3/Beclin1 Pathway. Dig Dis Sci 68, 1280–1291 (2023). https://doi.org/10.1007/s10620-022-07653-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-022-07653-y